Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors

World Journal of Urology

Volumn 31, Issue 4, 2013, Pages 805-809

  Weikert, Steffen ^a   Kempkensteffen, Carsten ^a   Busch, Jonas ^a   Johannsen, Manfred ^a   Grünwald, Viktor ^b   Zimmermann, Kaja ^a   Flörcken, Anne ^a   Westermann, Jörg ^a   Weinkauf, Lisa ^a   Miller, Kurt ^a   Keilholz, Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Adverse event; Drug; Kidney cancer; Metastasis; Survival; Toxicity

Indexed keywords

CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; INDOLE DERIVATIVE; MTOR PROTEIN, HUMAN; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; RAPAMYCIN; SORAFENIB; SUNITINIB; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; DISEASE COURSE; DRUG ANTAGONISM; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84881076051     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0676-1     Document Type: Article

References (17)

1. Weikert S, Ljungberg B (2010) Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World J Urol 28: 247-252. doi: 10. 1007/s00345-010-0555-1.
2. Herrmann E, Bierer S, Wulfing C (2010) Update on systemic therapies of metastatic renal cell carcinoma. World J Urol 28: 303-309. doi: 10. 1007/s00345-010-0519-5.
3. Ravaud A, Wallerand H, Culine S, Bernhard JC, Fergelot P, Bensalah K, Patard JJ (2008) Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 54: 315-325. doi: 10. 1016/j. eururo. 2008. 04. 056.
4. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456. doi: 10. 1016/S0140-6736(08)61039-9.
5. Kapoor A, Figlin RA (2009) Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer 115: 3618-3630. doi: 10. 1002/cncr. 24409.
6. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger A (2010) Guidelines on renal cell carcinoma. European association of urology web site. http://www. uroweb. org/?id=218&gid=4. Updated 2010. Accessed May 15, 2010.
7. Gerullis H, Bergmann L, Maute L, Ecke TH, Eimer C, Bagner JW, Otto T (2010) Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol 27: 373-378. doi: 10. 1007/s12032-009-9220-1.
8. Mackenzie MJ, Rini BI, Elson P, Schwandt A, Wood L, Trinkhaus M, Bjarnason G, Knox J (2010) Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann Oncol [Epub ahead of print]. doi: 10. 1093/annonc/mdq320.
9. Di Lorenzo G, Carteni G, Autorino R et al (2009) Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol 27: 4469-4474. doi: 10. 1200/JCO. 2009. 22. 6480.
10. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C (2009) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115: 61-67. doi: 10. 1002/cncr. 24009.
11. Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H (2008) Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 54: 1373-1378. doi: 10. 1016/j. eururo. 2008. 07. 051.
12. Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier C, Medioni J, Escudier B (2009) Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 182: 29-34 (discussion 34). doi: 10. 1016/j. juro. 2009. 02. 119.
13. Zimmermann K, Schmittel A, Steiner U, Asemissen AM, Knoedler M, Thiel E, Miller K, Keilholz U (2009) Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 76: 350-354. doi: 10. 1159/000209961.
14. Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM (2008) Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179: 81-86 (discussion 86). doi: 10. 1016/j. juro. 2007. 08. 127.
15. Rodriguez-Pascual J, Cheng E, Maroto P, Duran I (2010) Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 21: 478-486.
16. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, Patenaude F, Oudard S, Karakiewicz PI (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53: 917-930. doi: 10. 1016/j. eururo. 2007. 11. 037.
17. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281. doi: 10. 1056/NEJMoa066838.